Zheng Rong Li

US Patent:

7056663, Jun 6, 2006

Filed:

Mar 23, 2001

Appl. No.:

09/816460

Inventors:

Shanaz H. Dairkee - Orinda CA, US
Zheng Li - Hayward CA, US

Assignee:

California Pacific Medical Center - San Francisco CA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

Methods of determining the likelihood of the re-occurrence of tumors and of determining the aggressiveness of post-surgical treatment are provided which rely on analysis of a loss of heterogeneity at the particular chromosomal locus 3p24. 3. Loss of expression or hypermethylation of the thyroid hormone receptor β1 gene is also predictive of an increased re-occurrence of tumors.

US Patent:

20050130172, Jun 16, 2005

Filed:

Jan 27, 2004

Appl. No.:

10/765790

Inventors:

Chris Beard - Concord CA, US
Chris Burgess - Westwood MA, US
Allison Gannon - Walnut Creek CA, US
Jeanne Harvey - Livermore CA, US
John Lechner - Richmond CA, US
Zheng Li - Hayward CA, US

International Classification:

C12Q001/68
G06F019/00
G01N033/48
G01N033/50

US Classification:

435006000, 702020000

Abstract:

The present invention relates to methods for identifying among the genes that are down-regulated in cells or tissues having disease including cancer, the CpG sites within the CpG islands of said genes, wherein the identified CpG sites show great potential for diagnostic utility. In another aspect, the present invention also provides methods of using the selected CpG sites for purposes of diagnosis, prognosis, staging, assessing or monitoring the therapy of or recovery from a disease such as cancer.

US Patent:

20050214812, Sep 29, 2005

Filed:

Jun 7, 2005

Appl. No.:

11/010980

Inventors:

Zheng Li - Hayward CA, US
Jeanne Harvey - Livermore CA, US

International Classification:

C12Q001/68
C12P019/34

US Classification:

435006000, 435091200

Abstract:

The present invention relates to detecting the relative methylation levels at one or more CpG sites on a nucleic acid molecule, by using the methylation specific primer extension reaction (MSPE). MSPE uses an agent to modify unmethylated cytosine at a CpG site to uracil and subsequently amplify the chemically treated nucleic acids. The MSPE primers distinguishing between unmethylated and methylated CpG sites are provided to conduct MSPE. Relative methylation levels at one or more CpG sites are performed by detecting the signal intensity of labels incorporated into the MSPE reaction products.

US Patent:

20100136541, Jun 3, 2010

Filed:

Jun 23, 2009

Appl. No.:

12/489502

Inventors:

Chris Beard - Concord CA, US
Chris Burgess - Westwood MA, US
Allison Gannon - Walnut Creek CA, US
Jeanne Harvey - Mountain View CA, US
John F. Lechner - Richmond CA, US
Zheng Li - San Ramon CA, US

Assignee:

Siemens Healthcare Diagnostics Inc. - Tarrytown NY

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention relates to methods for identifying among the genes that are down-regulated in cells or tissues having disease including cancer, the CpG sites within the CpG islands of said genes, wherein the identified CpG sites show great potential for diagnostic utility. In another aspect, the present invention also provides methods of using the selected CpG sites for purposes of diagnosis, prognosis, staging, assessing or monitoring the therapy of or recovery from a disease such as cancer.

US Patent:

20210254181, Aug 19, 2021

Filed:

Apr 20, 2021

Appl. No.:

17/301976

Inventors:

- Carlsbad CA, US
Pius BRZOSKA - Woodside CA, US
Zheng LI - San Ramon CA, US
Wendy LIN - San Francisco CA, US
Wing LEE - San Leandro CA, US
Mandi WONG - South San Francisco CA, US

International Classification:

C12Q 1/6886
C12Q 1/6858
C12Q 1/6851

Abstract:

A method, comprising amplifying a nucleic acid sequence of interest in a sample comprising genomic DNA of a subject; amplifying a reference nucleic acid sequence in the sample; quantifying the amplified sequence of interest relative to the amplified reference sequence; and determining a copy number of the sequence of interest from the relative quantified amplified sequence of interest. The reference sequence may have at least 80% sequence identity to at least one of SEQ ID NO:1-38, such as SEQ ID NO:1-13. Also disclosed are kits and compositions, each comprising a first probe which specifically hybridizes to at least a portion of at least one reference sequence. Also disclosed is a system configured to perform the above method.

US Patent:

20200126210, Apr 23, 2020

Filed:

Oct 16, 2019

Appl. No.:

16/654200

Inventors:

- South San Francisco CA, US
Zheng Li - South San Francisco CA, US

Assignee:

GENENTECH, INC. - South San Francisco CA

International Classification:

G06T 7/00
G06N 20/00
G06N 3/04
G06F 17/15
G06F 16/53

Abstract:

In one embodiment, a method includes receiving one or more querying images associated with a container of a pharmaceutical product, each of the one or more querying images being based on a particular angle of the container of the pharmaceutical product, calculating one or more confidence scores associated with one or more defect indications, respectively for the container of the pharmaceutical product, by processing the one or more querying images using a target machine-learning model, and determining a defect indication for the container of the pharmaceutical product from the one or more defect indications based on a comparison between the one or more confidence scores and one or more predefined threshold scores, respectively.

US Patent:

20170096711, Apr 6, 2017

Filed:

Mar 20, 2015

Appl. No.:

15/128076

Inventors:

- Carlsbad CA, US
Pius BRZOSKA - Woodside CA, US
Zheng LI - San Ramon CA, US
Wendy LIN - San Francisco CA, US
Wing LEE - San Leandro CA, US
Mandi WONG - South San Francisco CA, US

International Classification:

C12Q 1/68

Abstract:

A method, comprising amplifying a nucleic acid sequence of interest in a sample comprising genomic DNA of a subject; amplifying a reference nucleic acid sequence in the sample; quantifying the amplified sequence of interest relative to the amplified reference sequence; and determining a copy number of the sequence of interest from the relative quantified amplified sequence of interest. The reference sequence may have at least 80% sequence identity to at least one of SEQ ID NO:1-38, such as SEQ ID NO:1-13. Also disclosed are kits and compositions, each comprising a first probe which specifically hybridizes to at least a portion of at least one reference sequence. Also disclosed is a system configured to perform the above method.

US Patent:

20160237076, Aug 18, 2016

Filed:

Jan 11, 2016

Appl. No.:

14/992396

Inventors:

- Oakland CA, US
Zheng Li - Oakland CA, US
Raymond M. Gipson - Los Angeles CA, US
Jue Wang - Los Angeles CA, US
Arnon Lavie - Chicago IL, US
Jennifer M. Murphy - Los Angeles CA, US
David A. Nathanson - Los Angeles CA, US
Michael E. Jung - Los Angeles CA, US

International Classification:

C07D 417/12
C07D 413/12
C07B 59/00

Abstract:

Provided herein are compounds that bind to dCK and methods for treating cancer.